srch

The Lancet family of journals publishes the latest COVID-19 related content across epidemiology, treatments, vaccines and much more.

17.12.2021 · On Dec 13, 2021, the UK Health Security Agency (UKHSA) confirmed that a patient in England had died after contracting the omicron variant of SARS-CoV-2. The previous day, prime minister Boris Johnson launched a drive to offer all adults in the UK a third dose of the COVID-19 vaccine by the end of the year. “We are now facing an emergency”, stated Johnson.

A large-scale UK study to investigate SARS-CoV-2 infections published in The Lancet Infectious Diseases has found that COVID-19 vaccines are effective at ...

2 days ago · On Jan 2, 2022, Israel's prime minister Naftali Bennett announced that the country would offer a fourth dose of the COVID-19 vaccine to health-care workers and people older than 60 years. A fourth dose has already been approved for Israelis in immunocompromised groups. Israel has recently seen a surge in SARS-CoV-2 infections. Hospitalisations are also increasing, though overall numbers remain ...

11.01.2022 · Welcome to the Lancet COVID-19 Resource Centre, bringing together all COVID-19 research, reviews, commentary, news, and analysis from across the Lancet family of journals as it is published. The resource aims to assist health workers, policy makers, and researchers to bring the COVID-19 pandemic to ...

Ranking by reported efficacy gives relative risk reductions of 95% for the Pfizer–BioNTech, 94% for the Moderna–NIH, 91% for the Gamaleya, 67% ...

23.12.2021 · Although effective COVID-19 vaccines are widely available in industrialised, wealthy countries and rates of vaccine coverage have reached 60–80%, availability of effective vaccines in lower-income and middle-income countries is lagging, with vaccine coverage only 5–30% in many countries and less than 5% in the poorest countries.

8) and people who were unvaccinated, not fully vaccinated, or whose vaccination status was unknown (median 21·5), indicating a high viral load ...

Jan 11, 2022 · Explore the latest COVID-19 related research, reviews, commentary, news and analysis across epidemiology, treatments, vaccines and much more from across the Lancet family of journals. Search all COVID-19 content published by the Lancet journals here.

Sep 13, 2021 · COVID-19 vaccines continue to be effective against severe disease, including that caused by the delta variant.

07.07.2021 · A peer-reviewed study of the "prestigious" scientific propaganda pamphlet "The Lancet", which had a moment of clarity for once, and published this, confirms that the efficacy of the "vaccine" is not 95%, as claimed by the vaccine companies, but remains at 1.3% for Astra Zeneca, 1.2% for Jannsen, 0.84% for Pfizer and 1.2% for Moderna.…

In a pivotal randomised controlled trial, the BNT162b2 mRNA vaccine (tozinameran, Pfizer–BioNTech) showed 95% or greater efficacy against ...

On Dec 13, 2021, the UK Health Security Agency (UKHSA) confirmed that a patient in England had died after contracting the omicron variant of SARS-CoV-2. The previous day, prime minister Boris Johnson launched a drive to offer all adults in the UK a third dose of the COVID-19 vaccine by the end of the year. “We are now facing an emergency”, stated Johnson. “There is a tidal wave of ...

High COVID-19 vaccination rates were expected to reduce transmission of SARS-CoV-2 in populations by reducing the number of possible sources ...

03.12.2021 · Her la nd Report: Sharply rising Covid rates among the Vaccinated: A recent report by The Lancet concludes that the mass vaccination process world wide has failed in halting the Covid transmissions.. New data shows that the virus is increasing in fully vaccinated individuals: “This proportion is increasing week by week and was 58.9% on 27.

20.04.2021 · Approximately 96 COVID-19 vaccines are at various stages of clinical development.1 At present, we have the interim results of four studies published in scientific journals (on the Pfizer–BioNTech BNT162b2 mRNA vaccine,2 the Moderna–US National Institutes of Health [NIH] mRNA-1273 vaccine,3 the AstraZeneca–Oxford ChAdOx1 nCov-19 …

2 dager siden · On Jan 2, 2022, Israel's prime minister Naftali Bennett announced that the country would offer a fourth dose of the COVID-19 vaccine to health-care workers and people older than 60 years. A fourth dose has already been approved for Israelis in immunocompromised groups. Israel has recently seen a surge in SARS-CoV-2 infections.

Vaccine effectiveness studies have conclusively demonstrated the benefit of COVID-19 vaccines in reducing individual symptomatic and severe ...

Apr 20, 2021 · Approximately 96 COVID-19 vaccines are at various stages of clinical development.1 At present, we have the interim results of four studies published in scientific journals (on the Pfizer–BioNTech BNT162b2 mRNA vaccine,2 the Moderna–US National Institutes of Health [NIH] mRNA-1273 vaccine,3 the AstraZeneca–Oxford ChAdOx1 nCov-19 vaccine,4 and the Gamaleya GamCovidVac [Sputnik V] vaccine)5 ...

19.11.2021 · High COVID-19 vaccination rates were expected to reduce transmission of SARS-CoV-2 in populations by reducing the number of possible sources for transmission and thereby to reduce the burden of COVID-19 disease. Recent data, however, indicate that the epidemiological relevance of COVID-19 vaccinated individuals is increasing. In the UK it was described that …

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK ...

13.09.2021 · Considerations in boosting COVID-19 vaccine immune responses. A new wave of COVID-19 cases caused by the highly transmissible delta variant is exacerbating the worldwide public health crisis, and has led to consideration of the potential need for, and optimal timing of, booster doses for vaccinated populations.

Oct 29, 2021 · Linked Articles. COVID-19 vaccines that have obtained WHO emergency use listing appear to have high efficacy against severe disease and death, but lower efficacy against non-severe infections, and emerging evidence suggests that protection against non-severe disease declines faster following vaccination than that against severe disease and death.

29.10.2021 · COVID-19 vaccines that have obtained WHO emergency use listing appear to have high efficacy against severe disease and death, but lower efficacy against non-severe infections, and emerging evidence suggests that protection against non-severe disease declines faster following vaccination than that against severe disease and death. What is less clear is …

Explore the latest COVID-19 related research, reviews, commentary, news and analysis across epidemiology, treatments, vaccines and much more from across the ...

In September, 2020, the WHO Prioritisation Roadmap for COVID-19 vaccines gave priority to prevention of severe disease and the highest risk ...